Vistagen Therapeutics Inc (VTGN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.24-1.38%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VTGN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -75.3% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 92.4% |
Growth built into the price is above our model estimate.
The price assumes 167.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
VTGN — earnings miss
Dated 2026-08-14
Results of Operations and Financial Condition. On August 14, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal year 2027 first quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Disclaimer. The information contained in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for pur…
Why it matters: How well Vistagen cuts costs shows its ability to manage rising expenses.
Watch forA report shows lower costs while clinical development stays on track.
Also watch forOperating costs keep going up even after cutting jobs.
Why it matters: Staying compliant is crucial for maintaining the company's listing and investor trust.
Worry ifThe company confirms it is in compliance with all Nasdaq Listing Rules.
Less concerning ifThe company gets a warning or does not follow Nasdaq Listing Rules.
Why it matters: These results are important for fasedienol's chance of approval for social anxiety disorder. Good results could help a future NDA.
Watch forTopline results show a clear improvement in the main goal for fasedienol.
Also watch forTopline results show no clear improvement in the main goal.
Why it matters: Changes in R&D spending will show how Vistagen is focusing on its clinical programs.
Watch forR&D costs drop a lot because the FDA supports fasedienol's development.
Also watch forR&D expenses go up or stay high, showing challenges in the development process.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$200 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $785 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,539 loss on $10,000 · 95.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The job cuts may affect how the company operates. This could hurt finances and project schedules.
Worry ifReports show they manage costs well and work efficiently after the job cuts.
Less concerning ifThere may be more challenges or financial strain after the workforce cut.
Why it matters: The job cuts aim to make finances better. We will see if this works.
Worry ifNet loss goes down a lot after the job cuts.
Less concerning ifNet loss remains high or increases despite the workforce reduction.
Why it matters: Reducing costs could help manage expenses and improve how the company runs.
Supportive ifManagement reports that the workforce reduction is on track to meet the 20% target.
Worry ifThe company fails to achieve the planned 20% workforce reduction.
Why it matters: R&D expense trends will indicate how Vistagen manages its cash and future clinical trials.
Watch forR&D costs go down a lot due to cash-saving measures.
Also watch forR&D costs stay high or rise, showing bad cash management.
Why it matters: If healthcare sector growth picks up, it may help Vistagen's performance. This could signal a better environment for the company.
Supportive ifHealthcare sector revenue growth shows a rise back toward 10% or higher.
Worry ifHealthcare sector revenue growth keeps slowing down below current levels.
Why it matters: This meeting could explain the future of fasedienol for social anxiety disorder. Good FDA feedback could help with getting approval.
Supportive ifA public announcement will confirm the FDA meeting. It will say positive feedback was received.
Worry ifNo meeting happens or the FDA gives negative feedback on the development path.
Why it matters: Topline results will show how well fasedienol works for social anxiety disorder. Good results could make investors more confident.
Supportive ifTopline results show a small but important gain for patients with very severe social anxiety.
Worry ifTopline results show no important gain or worse results compared to the placebo.
Why it matters: Regaining compliance is crucial for Vistagen's continued listing on Nasdaq. Failure to comply could lead to delisting.
Worry ifVistagen meets Nasdaq listing rules by the deadline in February 2027.
Less concerning ifThe company fails to regain compliance by the February 2027 deadline.